Integration of various therapeutic modes and novel hypoxic
therapy are two emerging aspects in the current anti-
cancer field. Based on this, we designed a multifunctional therapeutic system combining
photothermal therapy (PTT), the newly defined chemodynamic
therapy (CDT) and AIPH-based hypoxic
therapy ingeniously, which can take effect well in hypoxic
tumor environments. The CuFeSe2-based heterojunction was controllably constructed by the coating of a MIL-100(Fe) shell layer by layer, and the large mesoporous cavities were subsequently filled with a polymerization initiator (AIPH) and phase change material (tetradecanol) to achieve higher drug loading and controlled heat release of radicals. When irradiated by a single 808 nm
laser, the photothermal agent of CuFeSe2 plays a significant role of the initiating switch in the whole nanoplatform, whose
hyperthermia not only realizes fundamental PTT but also promotes greatly the Fenton reaction of the MIL-100(Fe) shell for oxidative ˙OH production and the generation of toxic AIPH radicals while melting tetradecanol. Due to the sensitive heat-responsive
therapies independent of
oxygen concentration, the nanoplatform showed a superior
therapeutic effect for hypoxic
tumor environments. Besides, on account of the effective attenuation for X-rays and the presence of the magnetic
element Fe of CuFeSe2, the nanoplatform was also certified to be a superior diagnosis agent for computed tomography (CT) and magnetic resonance imaging (MRI). As expected, cell experiments in vitro and mice experiments in vivo further verified the excellent biocompatibility and antitumor effect, suggesting that this nanoplatform of CuFeSe2@
MIL-100(Fe)-AIPH is promising for simultaneous diagnosis and treatment in hypoxic
cancer therapy.